Induction of Apoptosis by Berberine in Hepatocellular Carcinoma HepG2 Cells via Downregulation of NF-κB. 2017

Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China.

Hepatocellular carcinoma (HCC) is highly resistant to traditional chemotherapeutic approaches, which causes difficulty in the development of effective drugs for the treatment of HCC. Berberine, a major ingredient of Rhizoma coptidis, is a natural alkaloid used in traditional Chinese medicine. Berberine exhibits potent antitumor activity against HCC due to its high efficiency and low toxicity. In the present study, we found that berberine sensitized HepG cells to NF-κB-mediated apoptosis. Berberine exhibited a significant antiproliferation effect on the HepG2 cells and promoted apoptosis. Both qRT-PCR and immunofluorescence staining revealed that berberine reduced the NF-κB p65 levels in HepG2 cells. Moreover, p65 overexpression rescued berberine-induced cell proliferation and prevented HepG2 cells from undergoing apoptosis. These results suggest that berberine inhibits the growth of HepG2 cells by promoting apoptosis through the NF-κB p65 pathway.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001599 Berberine An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. Umbellatine
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
March 2015, Oncology reports,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
August 2017, The international journal of biochemistry & cell biology,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
May 2018, Oncology letters,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
September 2013, European review for medical and pharmacological sciences,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
January 2016, Asian Pacific journal of cancer prevention : APJCP,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
January 2016, Cell death discovery,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
July 2016, Environmental toxicology and pharmacology,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
October 2013, Phytotherapy research : PTR,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
September 2015, Molecular medicine reports,
Min Li, and Mao Zhang, and Zhi-Lang Zhang, and Ning Liu, and Xiao-Yu Han, and Qin-Cheng Liu, and Wei-Jun Deng, and Cai-Xian Liao
February 2021, Human & experimental toxicology,
Copied contents to your clipboard!